Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 28,282,000, an increase of 7.6% compared to RMB 25,359,000 for the year ended December 31, 2024[6]. - Gross profit for the year was RMB 17,769,000, representing a gross margin of 62.8%, compared to RMB 17,072,000 and a gross margin of 67.3% in the previous year[6]. - Other income increased significantly to RMB 3,311,000 from RMB 698,000, marking a growth of 373.5% year-over-year[6]. - The total comprehensive loss for the year was RMB 4,628,000, slightly higher than the loss of RMB 4,465,000 in the previous year[6]. - The company reported a loss per share of RMB 1.00 for the year ended December 31, 2025, compared to RMB 0.86 in the previous year[7]. - The company reported a pre-tax loss of RMB 5,013 thousand for 2025, compared to a loss of RMB 4,158 thousand in 2024, indicating a deterioration in financial performance[24]. - As of December 31, 2025, the company reported a loss attributable to shareholders of approximately RMB 5.0 million, an increase of about RMB 855,000 or approximately 20.6% compared to the loss of RMB 4.2 million for the year ended December 31, 2024, primarily due to a significant increase in administrative expenses of about RMB 2.3 million[71]. Assets and Liabilities - The company's total assets as of December 31, 2025, were RMB 57,262,000, compared to RMB 54,723,000 in 2024, reflecting a growth of 4.6%[8]. - Current liabilities increased to RMB 14,754,000 from RMB 11,166,000, representing a rise of 32.5% year-over-year[8]. - The net current asset value was RMB 42,508,000, slightly down from RMB 43,557,000 in the previous year[8]. - The company's net asset value as of December 31, 2025, is RMB 51,156,000, compared to RMB 54,048,000 in 2024, reflecting a decrease of approximately 5.4%[9]. - The company's total equity attributable to owners is RMB 51,131,000 in 2025, down from RMB 54,048,000 in 2024, indicating a decline of about 5.4%[9]. - The company's share capital increased to RMB 4,568,000 in 2025 from RMB 4,432,000 in 2024, representing a growth of approximately 3.1%[9]. - The company's reserves decreased to RMB 46,563,000 in 2025 from RMB 49,616,000 in 2024, showing a reduction of about 6.2%[9]. Research and Development - Research and development expenses rose to RMB 3,249,000, up from RMB 2,825,000, indicating a year-over-year increase of 15.0%[6]. - The company plans to continue investing in research and development to enhance its product offerings and market presence[5]. - Research and development expenses increased by approximately RMB 424,000 or 15.0% to approximately RMB 3.2 million for the year ending December 31, 2025, driven by increased employee costs for improving existing products and developing new infertility reagents and health products[69]. Market and Product Strategy - The company is primarily engaged in the research, production, marketing, and sales of biopharmaceuticals and health products in China[11]. - The company plans to continue expanding its market presence and product offerings, focusing on biological agents and health products[23]. - The group aims to transform its women's health division into a comprehensive health service provider, integrating functional supplements with professional nursing services[58]. - The group is strategically targeting the aging population and developing precise anti-aging solutions to meet the growing demand for longevity health[59]. - The group will continue to invest in product development in Canada and China, ensuring expansion plans are tailored to regional regulatory and competitive environments[60]. Shareholder and Corporate Governance - The company has adopted and complied with the corporate governance code as per GEM listing rules during the relevant period[89]. - The company confirms compliance with the minimum public float requirement of 25% under GEM listing rules as of the announcement date[95]. - The audit committee consists of three independent non-executive directors, ensuring compliance with GEM listing rules[102]. - The financial statements have been reviewed and deemed compliant with applicable accounting standards and GEM listing requirements[103]. - The annual report for the year ending December 31, 2025, will be distributed to shareholders and published on the company's website[104]. Employee and Operational Costs - Employee costs, including director remuneration, rose to RMB 17,060,000 in 2025 from RMB 16,153,000 in 2024, reflecting a year-over-year increase of about 5.6%[36]. - The company had 101 full-time employees as of December 31, 2025, an increase from 91 employees in the previous year, with employee costs recognized in profit or loss amounting to approximately RMB 17.1 million[82]. - The company's inventory cost included employee costs, amortization, depreciation, and other lease-related expenses totaling approximately RMB 3,035,000 in 2025, compared to RMB 2,896,000 in 2024, marking an increase of about 4.8%[36]. Acquisitions and Investments - The company acquired 91% of Hunan Keyue Biotechnology Co., Ltd. for a cash consideration of RMB 317,000, enhancing its strategy in the women's health market[50]. - The identifiable net assets of Keyue at the acquisition date were valued at approximately RMB 349,000[52]. - The revenue contribution from Keyue since the acquisition was approximately RMB 2,750,000, with a loss contribution of RMB 77,000[53]. Compliance and Legal Matters - There are no significant legal proceedings or arbitrations involving the company as of December 31, 2025[96]. - The company has not entered into any agreements that would result in the issuance of shares or require the company to enter into any agreements that may lead to share issuance[92]. - The company has not engaged in any purchases, sales, or redemptions of its listed securities during the relevant period[93].
愉悦集团(08622) - 2025 - 年度业绩